KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Depreciation and Depletion: 2017-2018

Historic Depreciation and Depletion for Amneal Pharmaceuticals (AMRX) over the last 2 years, with Dec 2018 value amounting to $18.6 million.

  • Amneal Pharmaceuticals' Depreciation and Depletion rose 56.19% to $18.6 million in Q4 2018 from the same period last year, while for Dec 2018 it was $60.9 million, marking a year-over-year change of. This contributed to the annual value of $62.6 million for FY2024, which is 5.44% down from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Depreciation and Depletion of $18.6 million as of Q4 2018, which was up 7.25% from $17.4 million recorded in Q3 2018.
  • In the past 5 years, Amneal Pharmaceuticals' Depreciation and Depletion registered a high of $18.6 million during Q4 2018, and its lowest value of $9.7 million during Q2 2017.
  • In the last 2 years, Amneal Pharmaceuticals' Depreciation and Depletion had a median value of $12.5 million in 2017 and averaged $13.5 million.
  • Data for Amneal Pharmaceuticals' Depreciation and Depletion shows a peak YoY soared of 62.53% (in 2018) over the last 5 years.
  • Amneal Pharmaceuticals' Depreciation and Depletion (Quarterly) stood at $11.9 million in 2017, then skyrocketed by 56.19% to $18.6 million in 2018.
  • Its Depreciation and Depletion stands at $18.6 million for Q4 2018, versus $17.4 million for Q3 2018 and $13.0 million for Q2 2018.